U.S. Electrical Stock News

Paychex (PAYX) has quietly lagged the market this year, with the stock down about 17% year to date even as the business keeps posting steady mid single digit revenue and double digit profit growth. See our latest analysis for Paychex. Despite the weak year to date share price return of around 16 percent, recent weeks have seen a modest rebound, and the three year total shareholder return of roughly 11 percent shows the long term story is intact rather than broken. If Paychex has you...

Fermi (FRMI) just hit an inflection point after its first investment grade tenant walked away from a $150 million construction funding agreement tied to Project Matador, sending the stock sharply lower and shaking near term confidence. See our latest analysis for Fermi. The terminated funding agreement did not just knock sentiment today; it capped a brutal stretch where the share price return is down 53 percent over 30 days and 73 percent year to date, even as Fermi continued to sign power...

In October 2025, Rayonier Inc. declared a special dividend of US$1.40 per common share, which was paid on December 12, 2025, and subsequently filed an omnibus shelf registration covering multiple securities, including debt, common and preferred shares, warrants, subscription rights, stock purchase contracts, and units. This combination of an immediate cash return to shareholders and expanded flexibility to raise capital in the future reflects Rayonier’s twin focus on rewarding investors...

In recent days, Elevance Health highlighted AM Best’s affirmation and upgrades of several subsidiary credit ratings and announced that healthcare executive and investor Amy Schulman will join its board as an independent director in January 2026, while also expanding its AI-powered Virtual Assistant to support roughly 22 million commercial members. Together, these developments underscore Elevance Health’s focus on shoring up financial resilience, strengthening governance oversight, and using...

Recent performance and setup DENTSPLY SIRONA (XRAY) has quietly bounced about 8% over the past month, even as the stock remains down sharply this year, setting up an interesting reset in expectations for long term investors. See our latest analysis for DENTSPLY SIRONA. That recent 1 month share price return of about 8% is a welcome change of pace, but it comes against a much tougher backdrop, with the year to date share price return down sharply and multi year total shareholder returns still...

Amphastar Pharmaceuticals recently received FDA approval for its abbreviated new drug application (ANDA) for a teriparatide injection prefilled pen, a single‑patient‑use product deemed bioequivalent and therapeutically equivalent to Eli Lilly’s FORTEO, with a U.S. market estimated at about US$585 million in sales over the 12 months to 30 September 2025. The company’s decision to manufacture this teriparatide product entirely in-house at its U.S. facility highlights its emphasis on domestic...

Bunge Global SA recently announced that co-Chief Operating Officer David Mattiske stepped down from his executive role on December 11, 2025, with fellow co-COO Julio Garros elevated to sole Chief Operating Officer while Christos Dimopoulos takes over as chief sustainability officer. These leadership moves, following the Viterra acquisition and reshuffling of the sustainability portfolio, point to a deeper consolidation of Bunge’s operating and ESG decision-making under a streamlined...

Karman Holdings (KRMN) has quietly turned into one of this year’s stronger industrial stories, with the stock up about 126% year to date and another 13% over the past month. See our latest analysis for Karman Holdings. That surge has come as investors warm to Karman’s role in high priority defense and space programs, with a 1 month share price return near 13% reinforcing a clear upward momentum trend this year from a modest recent pullback at $68.06. If Karman’s run has you rethinking what...

W.W. Grainger (GWW) has quietly pushed higher in recent weeks, with the stock up about 7% over the past week and roughly 11% in the past month after a tough start to the year. See our latest analysis for W.W. Grainger. That bounce has only partly repaired the damage from earlier in the year, with the year to date share price return still slightly negative and the 1 year total shareholder return in the red. However, multi year total shareholder returns remain very strong, suggesting long term...

WEC Energy Group (WEC) just paired fresh 2026 earnings guidance with plans for a higher 2026 dividend, sending a clear signal about management’s confidence in both cash flow durability and long term growth. See our latest analysis for WEC Energy Group. The guidance and dividend news land after a choppy stretch, with a negative 30 day share price return but an 11.99% year to date share price return and resilient 5 year total shareholder return of 39.05%, suggesting steady compounding rather...

Biogen (BIIB) has been back in the spotlight after fresh data on two key neurology programs, zorevunersen for Dravet syndrome and subcutaneous lecanemab for Alzheimer’s, landed at major medical meetings this month. See our latest analysis for Biogen. Those upbeat data drops seem to be breathing life back into sentiment, with a 21.31 percent 3 month share price return and a stronger 1 year total shareholder return of 16.66 percent, even though the 5 year total shareholder return of negative...

Mohawk Industries (MHK) is back in the spotlight as fresh analysis points to two years of stalled organic revenue growth, weakening returns on invested capital, and disappointing cash conversion. This is sharpening questions around its long term strategy. See our latest analysis for Mohawk Industries. Despite a modest 1 month share price return of 4.24 percent and a 7 day share price gain of 2.57 percent, the 1 year total shareholder return of negative 12.01 percent and 5 year total...

Gartner (IT) just caught investors attention again after a director bought shares and management authorized a record $1 billion buyback, which some see as a signal of confidence even as growth and margins face pressure. See our latest analysis for Gartner. The latest bounce, including a 5.33% 1 day share price return and 8.39% 7 day share price return to $246.35, has eased some nerves. However, it comes after a brutal year to date share price decline of 49.03 percent and a 1 year total...

MPLX (MPLX) has quietly outperformed much of the midstream space over the past year, and that kind of steady climb usually signals investors see more than just a generous payout. See our latest analysis for MPLX. At a share price of about $54.90, MPLX has logged a solid 12.9 percent year to date share price return, while its 24.4 percent one year total shareholder return suggests momentum is still building rather than fading. If MPLX's steady climb has you thinking about broader income and...

Xenia Hotels & Resorts recently completed a major share repurchase program, buying back 3,717,939 shares for US$48.91 million between July 1 and December 4, 2025, and in total retiring 28,230,533 shares for US$377.5 million since the program began in 2015. By shrinking its share count by over a quarter through this long-running buyback, the company has materially increased each remaining investor’s claim on future cash flows and earnings. We’ll now examine how completing this extensive...

Lennar Corporation reported its Q4 2025 results after the market close on December 16, 2025, following a prior quarter in which it missed analysts’ revenue and adjusted operating income estimates and saw revenue fall 6.4% year on year. Investor focus has intensified ahead of this latest release because Lennar has become the most shorted stock in the consumer discretionary sector, with very large short interest in its free float. We’ll now explore how elevated short interest heading into...

Growing investor interest in American Healthcare REIT American Healthcare REIT is getting more attention as investors search for steadier ideas in a choppy market, thanks to its diversified healthcare real estate portfolio and buzz around a potential public listing. See our latest analysis for American Healthcare REIT. That backdrop helps explain the mixed recent moves, with a 7 day share price return of minus 5.3 percent and a 90 day share price return of 11.6 percent. These feed into a...

Earlier in December 2025, Crinetics Pharmaceuticals began dosing patients in its first-in-human Phase 1/2 BRAVESST2 trial of CRN09682, a nonpeptide drug conjugate targeting SST2-positive neuroendocrine and other SST2-expressing solid tumors, while also advancing atumelnant into a Phase 3 trial for congenital adrenal hyperplasia with Orphan Drug Designation. This marks an important test of Crinetics’ proprietary NDC platform, which aims to combine targeted tumor delivery with simpler...

Chesapeake Utilities stock snapshot after recent pullback Chesapeake Utilities (CPK) has slipped about 6% over the past month, even as its year to date gain sits near 6%, inviting a closer look at whether the recent weakness creates opportunity. See our latest analysis for Chesapeake Utilities. That 5.8% 1 month share price pullback looks more like a breather within a still positive trend. The 90 day share price return is in the low single digits, and a solid 5 year total shareholder return...

Helmerich & Payne recently announced that long-time CEO and director John Lindsay will retire after the March 4, 2026 Annual Meeting, with President Raymond John “Trey” Adams set to assume the CEO role and join the Board, while Lindsay remains as senior advisor through December 2026 to support the transition. This planned leadership handover, following a tenure marked by FlexRig innovation, technology acquisitions and international expansion, raises important questions about how Adams will...

Earlier this month, Herc Holdings Inc. announced it had priced US$600 million of 5.750% senior unsecured notes due 2031 and US$600 million of 6.000% notes due 2034, planning to use the proceeds along with its ABL credit facility to redeem US$1.20 billion of 5.50% senior notes due 2027, while its board also declared a US$0.70 quarterly dividend payable on December 26, 2025. This combination of refinancing longer-dated debt while maintaining a regular cash dividend highlights management’s...

In recent weeks, JOYY Inc. was highlighted for offering an around 9% total shareholder yield through dividends and buybacks, while trading below its net cash position and reporting strong growth in non-live streaming segments such as BIGO Ads and e-commerce SaaS. An interesting angle is JOYY’s push into AI-driven AdTech and planned 2026 iOS expansion, which could further shift its revenue mix toward higher-margin, advertising-led and software-based businesses. We’ll now explore how JOYY’s...

IDEAYA Biosciences (IDYA) just hit a key clinical milestone, completing enrollment in its pivotal OptimUM-02 trial of darovasertib for metastatic uveal melanoma, with additional IND clearances quietly broadening the pipeline behind that lead asset. See our latest analysis for IDEAYA Biosciences. The clinical momentum around darovasertib and fresh IND wins has helped IDEAYA build a strong backdrop, with a roughly 36 percent 3 month share price return and a standout 5 year total shareholder...

In recent days, Dimerix announced that its ACTION3 Phase 3 trial of DMX-200 for focal segmental glomerulosclerosis completed recruitment and dosing of 286 adult patients, while Amicus Therapeutics drew fresh attention after new analyst coverage highlighted the company’s earnings potential. Together, the late-stage progress of DMX-200 and the wave of optimistic research coverage sharpen the focus on Amicus’s pipeline depth and prospects for earnings improvement. Now we’ll examine how this...